Récepteur muscarinique de type M1 : Questions médicales fréquentes
Nom anglais: Receptor, Muscarinic M1
Descriptor UI:D043643
Tree Number:D12.776.543.750.720.360.500.099
Termes MeSH sélectionnés :
Data Collection
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Récepteur muscarinique de type M1 : Questions médicales les plus fréquentes",
"headline": "Récepteur muscarinique de type M1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Récepteur muscarinique de type M1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-01",
"dateModified": "2025-02-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Récepteur muscarinique de type M1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Récepteur muscarinique",
"url": "https://questionsmedicales.fr/mesh/D011976",
"about": {
"@type": "MedicalCondition",
"name": "Récepteur muscarinique",
"code": {
"@type": "MedicalCode",
"code": "D011976",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.750.720.360.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Récepteur muscarinique de type M1",
"alternateName": "Receptor, Muscarinic M1",
"code": {
"@type": "MedicalCode",
"code": "D043643",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Brian Dean",
"url": "https://questionsmedicales.fr/author/Brian%20Dean",
"affiliation": {
"@type": "Organization",
"name": "The Molecular Psychiatry Laboratory, The Florey Institute for Neuroscience and Mental Health, Parkville, Victoria 3052, Australia. Electronic address: brian.dean@florey.edu.au."
}
},
{
"@type": "Person",
"name": "Yu Qiu",
"url": "https://questionsmedicales.fr/author/Yu%20Qiu",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Chemical Biology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China."
}
},
{
"@type": "Person",
"name": "Louis Dwomoh",
"url": "https://questionsmedicales.fr/author/Louis%20Dwomoh",
"affiliation": {
"@type": "Organization",
"name": "The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom."
}
},
{
"@type": "Person",
"name": "Andrew B Tobin",
"url": "https://questionsmedicales.fr/author/Andrew%20B%20Tobin",
"affiliation": {
"@type": "Organization",
"name": "The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom."
}
},
{
"@type": "Person",
"name": "Lan-Xue Zhao",
"url": "https://questionsmedicales.fr/author/Lan-Xue%20Zhao",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology and Chemical Biology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Usability, Engagement, and Report Usefulness of Chatbot-Based Family Health History Data Collection: Mixed Methods Analysis.",
"datePublished": "2024-09-30",
"url": "https://questionsmedicales.fr/article/39348188",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/55164"
}
},
{
"@type": "ScholarlyArticle",
"name": "Strengthening systems of care for people with or at risk for HIV, HCV and opioid use disorder: a call for enhanced data collection.",
"datePublished": "2022-07-01",
"url": "https://questionsmedicales.fr/article/35775786",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/07853890.2022.2084154"
}
},
{
"@type": "ScholarlyArticle",
"name": "Head and Neck Paraganglioma (HNPGL) Registry: A study protocol for prospective data collection in patients with Head and Neck Paragangliomas.",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39052568",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0307311"
}
},
{
"@type": "ScholarlyArticle",
"name": "Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project.",
"datePublished": "2024-07-24",
"url": "https://questionsmedicales.fr/article/39044237",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-024-08317-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective.",
"datePublished": "2023-10-13",
"url": "https://questionsmedicales.fr/article/37901362",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/jpps.2023.11877"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Récepteurs de surface cellulaire",
"item": "https://questionsmedicales.fr/mesh/D011956"
},
{
"@type": "ListItem",
"position": 6,
"name": "Récepteurs aux neuromédiateurs",
"item": "https://questionsmedicales.fr/mesh/D017981"
},
{
"@type": "ListItem",
"position": 7,
"name": "Récepteurs cholinergiques",
"item": "https://questionsmedicales.fr/mesh/D011950"
},
{
"@type": "ListItem",
"position": 8,
"name": "Récepteur muscarinique",
"item": "https://questionsmedicales.fr/mesh/D011976"
},
{
"@type": "ListItem",
"position": 9,
"name": "Récepteur muscarinique de type M1",
"item": "https://questionsmedicales.fr/mesh/D043643"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Récepteur muscarinique de type M1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Récepteur muscarinique de type M1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Récepteur muscarinique de type M1",
"description": "Comment diagnostiquer une dysfonction du récepteur M1 ?\nQuels tests sont utilisés pour évaluer le récepteur M1 ?\nQuels symptômes peuvent indiquer un problème avec le récepteur M1 ?\nY a-t-il des biomarqueurs pour le récepteur M1 ?\nComment les médicaments affectent-ils le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D043643?mesh_terms=Data+Collection&page=9#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Récepteur muscarinique de type M1",
"description": "Quels sont les symptômes d'une activation excessive du récepteur M1 ?\nQuels symptômes sont associés à une inhibition du récepteur M1 ?\nLes symptômes varient-ils selon l'âge ?\nComment les symptômes affectent-ils la vie quotidienne ?\nY a-t-il des symptômes physiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D043643?mesh_terms=Data+Collection&page=9#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Récepteur muscarinique de type M1",
"description": "Comment prévenir les dysfonctionnements du récepteur M1 ?\nL'alimentation joue-t-elle un rôle préventif ?\nLe stress a-t-il un impact sur le récepteur M1 ?\nLes exercices mentaux sont-ils bénéfiques ?\nY a-t-il des habitudes de vie à éviter ?",
"url": "https://questionsmedicales.fr/mesh/D043643?mesh_terms=Data+Collection&page=9#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Récepteur muscarinique de type M1",
"description": "Quels traitements sont disponibles pour les dysfonctionnements M1 ?\nLes médicaments anticholinergiques sont-ils efficaces ?\nLa thérapie comportementale aide-t-elle ?\nY a-t-il des traitements expérimentaux en cours ?\nComment la nutrition influence-t-elle le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D043643?mesh_terms=Data+Collection&page=9#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Récepteur muscarinique de type M1",
"description": "Quelles complications peuvent survenir avec une dysfonction M1 ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des risques de complications à long terme ?\nLes complications peuvent-elles être prévenues ?",
"url": "https://questionsmedicales.fr/mesh/D043643?mesh_terms=Data+Collection&page=9#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Récepteur muscarinique de type M1",
"description": "Quels sont les principaux facteurs de risque pour les dysfonctionnements M1 ?\nLe mode de vie influence-t-il les risques ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe stress chronique est-il un facteur de risque ?\nY a-t-il des facteurs environnementaux à considérer ?",
"url": "https://questionsmedicales.fr/mesh/D043643?mesh_terms=Data+Collection&page=9#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction du récepteur M1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests neuropsychologiques et l'imagerie cérébrale."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le récepteur M1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de liaison de ligands et des études électrophysiologiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec le récepteur M1 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la mémoire, de l'attention et des fonctions cognitives peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs pour le récepteur M1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de biomarqueurs spécifiques pour le récepteur M1."
}
},
{
"@type": "Question",
"name": "Comment les médicaments affectent-ils le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments peuvent masquer les symptômes liés à la dysfonction du récepteur M1."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une activation excessive du récepteur M1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive peut entraîner des troubles cognitifs et des hallucinations."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une inhibition du récepteur M1 ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inhibition peut causer des troubles de la mémoire et une diminution de l'attention."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus prononcés chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Comment les symptômes affectent-ils la vie quotidienne ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les troubles cognitifs peuvent nuire à l'autonomie et aux interactions sociales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes physiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes physiques comme des tremblements peuvent également être présents."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements du récepteur M1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir une activité cognitive et physique régulière peut aider à prévenir."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle préventif ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée riche en oméga-3 peut réduire les risques."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le récepteur M1 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un stress chronique peut altérer la fonction cognitive et affecter le récepteur M1."
}
},
{
"@type": "Question",
"name": "Les exercices mentaux sont-ils bénéfiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les exercices mentaux réguliers peuvent renforcer les connexions neuronales."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à éviter ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'alcool et le tabac peut réduire le risque de dysfonctionnement cognitif."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les dysfonctionnements M1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments anticholinestérasiques et des thérapies cognitives."
}
},
{
"@type": "Question",
"name": "Les médicaments anticholinergiques sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent aggraver les symptômes en bloquant l'action du récepteur M1."
}
},
{
"@type": "Question",
"name": "La thérapie comportementale aide-t-elle ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie comportementale peut améliorer les fonctions cognitives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux en cours ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sur des agonistes sélectifs du récepteur M1 sont en cours."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut soutenir la santé cognitive."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dysfonction M1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles sévères de la mémoire et des démences."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent gravement diminuer l'autonomie et la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications chroniques comme la démence existent."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être prévenues ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion proactive des symptômes peut aider à prévenir certaines complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les dysfonctionnements M1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les antécédents familiaux et les maladies neurodégénératives sont des facteurs."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de troubles neurologiques augmentent le risque de dysfonctionnement M1."
}
},
{
"@type": "Question",
"name": "Le stress chronique est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à la dégradation cognitive et au dysfonctionnement M1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à considérer ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut augmenter le risque de dysfonctionnement."
}
}
]
}
]
}
Family health history (FHx) is an important predictor of a person's genetic risk but is not collected by many adults in the United States....
This study aims to test and compare the usability, engagement, and report usefulness of 2 web-based methods to collect FHx....
This mixed methods study compared FHx data collection using a flow-based chatbot (KIT; the curious interactive test) and a form-based method. KIT's design was optimized to reduce user burden. We recru...
Participants randomized to KIT reported higher usability than those randomized to the form, with a mean System Usability Scale score of 80.2 versus 61.9 (P<.001), respectively. The engagement analysis...
We showed that KIT provided a usable way to collect FHx. We also identified design considerations to improve chatbot-based FHx data collection: First, the final report summarizing the FHx collection e...
The syndemic between opioid use disorder (OUD), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) results in excessive burdens on the healthcare system. Integrating these siloed systems ...
Data for this study were gathered from publicly available datasets and reports from government (SAMSHA, CMS, HRSA and CDC) sites. We created, where possible, COCs for HIV, HCV, and OUD spanning popula...
The process of data collection showed that baseline COCs examining the intersections of OUD, HIV, and HCV cannot be produced and that there are missing data in all states examined. Collection of speci...
It is difficult to assess the strategies needed or the progress made towards increasing treatment access and decreasing the burden of disease without the ability to construct an accurate baseline. Usi...
There is a lack of comprehensive and uniform data on head and neck paragangliomas (HNPGLs), and research is challenging due to its rarity and the involvement of multiple medical specialties. To improv...
The HNPGL Registry is designed as a prospective longitudinal observational registry for data collection on HNPGL patients and carriers of (likely) pathogenic variants causative of HNPGLs. All patients...
The HNPGL Registry data will be used to further establish the optimal management for HNPGL patients and lay the foundation for guideline recommendations and the outline of future research....
It is essential that electronic data collection (EDC) systems are both compliant with regulations and the principles of Good Clinical Practice (GCP) to allow for the timely and accurate reporting of d...
A multi-disciplinary working group came together from a UK academic clinical trials unit (CTU) to establish if an electronic system could be created in the unit's open-source EDC system-REDCap, to man...
A module has been created in REDCap to facilitate electronic SAE reporting: enabling an AE form to automatically trigger an SAE form for any AE which is also a SAE, prepopulating relevant fields of th...
The eSAE Project coded into REDCap offers a unique way of populating SAE forms with information already entered in the initial AE forms as applicable, coupled with highlighting any updates during the ...
Patient support programs (PSPs) offer a unique opportunity to collect real-world data that can contribute to improving patient care and informing healthcare decision making. In this perspective articl...
Adaptive deep brain stimulation (aDBS) shows promise for improving treatment for neurological disorders such as Parkinson's disease (PD). aDBS uses symptom-related biomarkers to adjust stimulation par...
There is increasing interest in collecting sociodemographic and social needs data in hospital settings to inform patient care and health equity. However, few studies have examined inpatients' views on...
A qualitative interpretive description methodology was used. Semi-structured interviews were conducted with 18 patients admitted to a large academic hospital in Toronto, Canada. Participants were recr...
Patients expressed that sociodemographic and social needs data collection is important to offer actionable solutions to address their needs. Patients described a gap between their ideal care which wou...
While the collection of sociodemographic and social needs information in hospital settings is generally acceptable, there were varied views on whether hospital staff should intervene, as their priorit...
The integration of health and activity data from various wearable devices into research studies presents technical and operational challenges. The Awesome Data Acquisition Method (ADAM) is a versatile...
Recently, unmanned aerial vehicles (UAVs) have emerged as a viable solution for data collection from remote Internet of Things (IoT) applications. However, the successful implementation in this regard...
The Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) seeks to provide comprehensive understanding of early-onset Alzheimer's disease (EOAD; onset <65 years), with the current study profiling...
Data from 371 LEADS participants were compared based on diagnostic group classification (cognitively normal [n = 89], amyloid-positive EOAD [n = 212], and amyloid-negative early-onset non-Alzheimer's ...
Cognitive performance was worse for EOAD than other groups, and EOAD participants were apolipoprotein E (APOE) ε4 homozygotes at higher rates. An amnestic presentation was common among impaired partic...
We present the most comprehensive baseline characterization of sporadic EOAD in the United States to date. EOAD presents with widespread cognitive impairment within and across clinical phenotypes, wit...
Findings represent the most comprehensive baseline characterization of sporadic early-onset Alzheimer's disease (EOAD) to date. Cognitive impairment was widespread for EOAD participants and more sever...
